Liposome-engineered therapeutics: A promising frontier in ovarian cancer treatment

IF 2.5 4区生物学 Q1 ANATOMY & MORPHOLOGY

Tissue & cell Pub Date : 2025-09-15 DOI:10.1016/j.tice.2025.103138

Helia Mavaddat , Amirreza Peyrovinasab , Shirin Sirous Kabiri , Nasim Basiri , Ilia Khayatan , Seyed Mehrad Razavi , Malak Hekmati , Atena Esmaeili , Tannaz Jamialahmadi , Amir Hossein Abdolghaffari , Prashant Kesharwani , Amirhossein Sahebkar

{"title":"Liposome-engineered therapeutics: A promising frontier in ovarian cancer treatment","authors":"Helia Mavaddat , Amirreza Peyrovinasab , Shirin Sirous Kabiri , Nasim Basiri , Ilia Khayatan , Seyed Mehrad Razavi , Malak Hekmati , Atena Esmaeili , Tannaz Jamialahmadi , Amir Hossein Abdolghaffari , Prashant Kesharwani , Amirhossein Sahebkar","doi":"10.1016/j.tice.2025.103138","DOIUrl":null,"url":null,"abstract":"<div><div>Ovarian cancer remains a leading cause of gynecological cancer-related mortality, with epithelial ovarian carcinoma, germ cell tumors, and stromal tumors being the most prevalent types. The disease is classified based on the Fédération Internationale de Gynécologie et d′Obstétrique (FIGO) staging system, and its incidence increases with age. Standard treatment strategies, including taxanes, platinum-based drugs, monoclonal antibodies, and poly (ADP-ribose) polymerase (PARP) inhibitors, as well as emerging gene and immunotherapies, often suffer from significant adverse effects and limited efficacy. To overcome these challenges, advanced drug delivery systems are essential for enhancing therapeutic outcomes while minimizing toxicity. Liposomes have emerged as a promising nanocarrier for targeted drug delivery in ovarian cancer therapy, offering improved drug stability, prolonged circulation time, and enhanced tumor-specific accumulation. Functional modifications, such as ligand conjugation and combination therapies, further optimize their therapeutic potential. This review discusses recent advancements in liposome-based drug delivery for ovarian cancer, highlighting their benefits, challenges, and future directions in improving treatment efficacy.</div></div>","PeriodicalId":23201,"journal":{"name":"Tissue & cell","volume":"98 ","pages":"Article 103138"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tissue & cell","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0040816625004203","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANATOMY & MORPHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Ovarian cancer remains a leading cause of gynecological cancer-related mortality, with epithelial ovarian carcinoma, germ cell tumors, and stromal tumors being the most prevalent types. The disease is classified based on the Fédération Internationale de Gynécologie et d′Obstétrique (FIGO) staging system, and its incidence increases with age. Standard treatment strategies, including taxanes, platinum-based drugs, monoclonal antibodies, and poly (ADP-ribose) polymerase (PARP) inhibitors, as well as emerging gene and immunotherapies, often suffer from significant adverse effects and limited efficacy. To overcome these challenges, advanced drug delivery systems are essential for enhancing therapeutic outcomes while minimizing toxicity. Liposomes have emerged as a promising nanocarrier for targeted drug delivery in ovarian cancer therapy, offering improved drug stability, prolonged circulation time, and enhanced tumor-specific accumulation. Functional modifications, such as ligand conjugation and combination therapies, further optimize their therapeutic potential. This review discusses recent advancements in liposome-based drug delivery for ovarian cancer, highlighting their benefits, challenges, and future directions in improving treatment efficacy.

查看原文本刊更多论文

脂质体工程疗法：卵巢癌治疗的一个有前途的前沿。

卵巢癌仍然是妇科癌症相关死亡的主要原因，其中上皮性卵巢癌、生殖细胞肿瘤和间质肿瘤是最常见的类型。该疾病的分类是基于fcv（国际女性组织）的分期系统，其发病率随着年龄的增长而增加。标准的治疗策略，包括紫杉烷、铂类药物、单克隆抗体和聚（adp -核糖）聚合酶（PARP）抑制剂，以及新兴的基因和免疫疗法，往往存在显著的不良反应和有限的疗效。为了克服这些挑战，先进的药物输送系统对于提高治疗效果同时最小化毒性至关重要。脂质体已成为卵巢癌治疗中有前景的靶向药物递送纳米载体，具有改善药物稳定性、延长循环时间和增强肿瘤特异性积累的特点。功能修饰，如配体偶联和联合治疗，进一步优化其治疗潜力。本文综述了基于脂质体的卵巢癌给药的最新进展，强调了它们的益处、挑战和提高治疗效果的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tissue & cell 医学-解剖学与形态学

CiteScore

3.90

自引率

0.00%

发文量

234

期刊介绍： Tissue and Cell is devoted to original research on the organization of cells, subcellular and extracellular components at all levels, including the grouping and interrelations of cells in tissues and organs. The journal encourages submission of ultrastructural studies that provide novel insights into structure, function and physiology of cells and tissues, in health and disease. Bioengineering and stem cells studies focused on the description of morphological and/or histological data are also welcomed. Studies investigating the effect of compounds and/or substances on structure of cells and tissues are generally outside the scope of this journal. For consideration, studies should contain a clear rationale on the use of (a) given substance(s), have a compelling morphological and structural focus and present novel incremental findings from previous literature.